Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a t… Read more
Shenzhen Chipscreen Biosciences Co (688321) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.001x
Based on the latest financial reports, Shenzhen Chipscreen Biosciences Co (688321) has a cash flow conversion efficiency ratio of 0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥2.25 Million) by net assets (CN¥1.66 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen Chipscreen Biosciences Co - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Shenzhen Chipscreen Biosciences Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shenzhen Chipscreen Biosciences Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Chipscreen Biosciences Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suess Microtec SE
LSE:0Q3C
|
0.019x |
|
Ladder Capital Corp Class A
NYSE:LADR
|
0.031x |
|
The Bank of East Asia Limited
PINK:BKEAF
|
-0.140x |
|
Visual Photonics Epitaxy Co Ltd
TW:2455
|
0.080x |
|
Leroy Seafood Group ASA
LSE:0GM2
|
0.061x |
|
Anhui Shenjian New Materials Co Ltd
SHE:002361
|
0.019x |
|
Birchcliff Energy Ltd.
PINK:BIREF
|
0.045x |
|
Paladin Energy Ltd
OTCQX:PALAF
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Shenzhen Chipscreen Biosciences Co (2016–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen Chipscreen Biosciences Co from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.58 Billion | CN¥76.13 Million | 0.048x | +157.49% |
| 2023-12-31 | CN¥1.71 Billion | CN¥-143.21 Million | -0.084x | -404.81% |
| 2022-12-31 | CN¥1.58 Billion | CN¥43.30 Million | 0.027x | -68.78% |
| 2021-12-31 | CN¥1.42 Billion | CN¥124.78 Million | 0.088x | +40.45% |
| 2020-12-31 | CN¥1.49 Billion | CN¥93.62 Million | 0.063x | +469.17% |
| 2019-12-31 | CN¥1.45 Billion | CN¥-24.55 Million | -0.017x | -135.54% |
| 2018-12-31 | CN¥476.90 Million | CN¥22.78 Million | 0.048x | +688.32% |
| 2017-12-31 | CN¥450.55 Million | CN¥2.73 Million | 0.006x | -97.84% |
| 2016-12-31 | CN¥213.40 Million | CN¥59.77 Million | 0.280x | -- |